日报更新时间：
周报更新时间：01-16 11:49
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
英文名称：NewLink Genetics
简介：Newlink Genetics Corporation是一家生物制药公司，专注于发现、开发和商业化免疫治疗产品，改善癌症患者的治疗方案
电话：1-515-2965555
NewLink Genetics公司主要从事小分子疫苗产品的制造与销售，产品包括治疗：胰脏癌、急性肺癌及黑色素瘤等免疫制品及药品等。其产品组合包括: 刺激人体免疫系统的基于其超急性免疫治疗技术的生物制品； 小分子候选产品，通过抑制indoleamine-(2,3)-dioxygenase和tryptophan-(2.3)-dioxygenase通路来突破免疫系统耐受癌症； HyperAcute Pancreas免疫疗法（主要候选产品，胰脏癌疫苗），已获美国FDA核准为胰腺癌的孤儿药，并进入III期临床试验阶段（2015.5.11——NewLink公司宣布该公司主打产品胰腺癌疫苗algenpantucel-L的III期数据没有显示进展，股价暴跌近30%，虽然这个药物拿到过Fda的快速批准通道，这个拖了好几年的III期研究就是这个公司用来大跌的利器。）； HyperAcute Lung免疫疗法，治疗晚期非小细胞肺癌； HyperAcute Melanoma免疫疗法，治疗晚期黑色素瘤； 肾癌、前列腺癌和乳腺癌免疫疗法； IDO通路抑制剂（包括indoximod和NLG919），用于治疗转移性乳腺癌和转移性前列腺癌;； NLG2101，治疗转移性乳腺癌； NLG2102，治疗难治性恶性脑肿瘤； NLG2103，治疗晚期黑色素瘤； NLG2014，治疗转移性胰腺癌。此外，NewLink Genetics公司还与默克公司合作开发埃博拉病毒疫苗。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-06-22 | Kennedy (Eugene P. M.D.) | Officer | Sell | 359 | 1.57 |
| 2019-01-03 | Link (Charles J Jr) | Chief Executive Officer | Sell | 5906 | 1.55 |
| 2019-01-03 | Vahanian (Nicholas N) | President | Sell | 2626 | 1.55 |
| 2019-01-03 | Kennedy (Eugene P. M.D.) | Officer | Sell | 376 | 1.55 |
| 2019-01-03 | Langren Carl W | Chief Financial Officer | Sell | 398 | 1.55 |
| 2019-01-01 | Langren Carl W | Chief Financial Officer | Sell | 646 | 1.66 |
| 2019-01-01 | Link (Charles J Jr) | Chief Executive Officer | Sell | 5699 | 1.66 |
| 2019-01-01 | Vahanian (Nicholas N) | President | Sell | 2229 | 1.66 |
| 2018-12-11 | Langren Carl W | Chief Financial Officer | Buy | 2564 | 0.80 |
| 2018-12-11 | Link (Charles J Jr) | Chief Executive Officer | Buy | 2564 | 0.80 |
| 2018-09-30 | Henneman (John Bell Iii) | Officer | Sell | 2484 | 2.28 |
| 2018-07-09 | Talarico (Ernest J III) | Director | Buy | 3571 | 2.10 |
| 2018-07-09 | Talarico (Ernest J III) | Director | Buy | 7142 | 2.10 |
| 2018-07-09 | Talarico (Ernest J III) | Director | Sell | 13806 | 4.82 |
| 2018-07-09 | Talarico (Ernest J III) | Director | Buy | 3093 | 2.10 |
| 2018-01-19 | Kennedy (Eugene P. M.D.) | Officer | Sell | 85 | 8.62 |
| 2018-01-03 | Wiley (Brian) | Officer | Sell | 603 | 10.06 |
| 2018-01-03 | Vahanian (Nicholas N) | President | Sell | 2659 | 10.06 |
| 2018-01-03 | Henneman (John Bell Iii) | Chief Financial Officer | Sell | 1323 | 10.06 |
| 2018-01-03 | Langren Carl W | Officer | Sell | 257 | 10.06 |
| 2018-01-03 | Link (Charles J Jr) | Chief Executive Officer | Sell | 5541 | 10.06 |
| 2018-01-03 | Kennedy (Eugene P. M.D.) | Officer | Sell | 409 | 10.06 |
| 2018-01-01 | Henneman (John Bell Iii) | Chief Financial Officer | Sell | 164 | 8.47 |
| 2018-01-01 | Link (Charles J Jr) | Chief Executive Officer | Sell | 8939 | 8.47 |
| 2018-01-01 | Wiley (Brian) | Officer | Sell | 1237 | 8.47 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Worth Venture Partners, LLC | 245649 | 0.66% | 245649 | -- | 2019-03-31 |
| Northern Trust Investments Inc | 520716 | 1.40% | -13511 | -2.53% | 2019-07-31 |
| State Street Corporation | 526561 | 1.41% | 5900 | 1.13% | 2019-03-31 |
| Connor Clark & Lunn Inv Mgmt Ltd | 628097 | 1.68% | -5500 | -0.87% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 667212 | 1.79% | -1285 | -0.19% | 2019-07-31 |
| Panagora Asset Management Inc | 671075 | 1.80% | -34246 | -4.86% | 2019-03-31 |
| Vanguard Group Inc | 1082390 | 2.90% | 225171 | 26.27% | 2019-03-31 |
| BlackRock Inc | 1815408 | 4.87% | -55719 | -2.98% | 2019-03-31 |
| Renaissance Technologies Corp | 2721813 | 7.30% | 660800 | 32.06% | 2019-03-31 |
| Wells Fargo & Co | 501693 | 1.35% | 563 | 0.11% | 2019-03-31 |
| Two Sigma Investments LLC | 497319 | 1.33% | 43063 | 9.48% | 2019-03-31 |
| Geode Capital Management, LLC | 487981 | 1.31% | -507531 | -50.98% | 2019-03-31 |
| Dimensional Fund Advisors LP | 266656 | 0.71% | -66234 | -19.90% | 2019-07-31 |
| Vanguard | 309233 | 0.83% | -- | -- | 2019-07-31 |
| Dimensional Fund Advisors, Inc. | 316045 | 0.85% | -59821 | -15.92% | 2019-03-31 |
| Fidelity Management & Research Company | 345291 | 0.93% | -7022 | -1.99% | 2019-07-31 |
| Northern Trust Investments N A | 345918 | 0.93% | -2845 | -0.82% | 2019-03-31 |
| Northern Trust Corp | 345918 | 0.93% | -2845 | -0.82% | 2019-03-31 |
| Acadian Asset Management LLC | 404083 | 1.08% | 404083 | -- | 2019-03-31 |
| Oxford Asset Management, LLC | 473761 | 1.27% | -122944 | -20.60% | 2019-03-31 |
| State Street Global Advisors | 296622 | 0.80% | -- | -- | 2019-06-30 |
| BlackRock Asset Management Canada Ltd | 638499 | 1.71% | -42 | -0.01% | 2019-05-31 |
| BlackRock Fund Advisors | 884264 | 2.37% | -400899 | -31.19% | 2019-05-31 |
| Anson Funds Management LP | 282262 | 0.76% | 282262 | -- | 2018-12-31 |
| J.P. Morgan Investment Management, Inc. | 477901 | 1.28% | 26291 | 5.82% | 2018-09-30 |
| J.P. Morgan Securities Inc | 662153 | 1.78% | 662153 | -- | 2018-09-30 |
| JPMorgan Chase & Co | 1156871 | 3.10% | 691651 | 148.67% | 2018-09-30 |
| BlackRock Institutional Trust Company NA | 716267 | 1.92% | -19564 | -2.66% | 2018-06-30 |
| Fidelity SelectCo, LLC | 658646 | 1.77% | 14 | -- | 2018-11-30 |
| Wells Fargo Advisors, LLC | 514126 | 1.38% | 5550 | 1.09% | 2018-09-30 |
| Alambic Investment Management, L.P. | 366995 | 0.99% | 314095 | 593.75% | 2018-06-30 |
| Columbia Mgmt Investment Advisers, LLC | 321746 | 0.86% | -- | -- | 2018-11-30 |
| UBS Asset Mgmt Americas Inc | 439967 | 1.18% | 427637 | 3468.26% | 2018-03-31 |
| Baker Bros Advisors LP | 507273 | 1.36% | -- | -- | 2018-06-30 |
| Fidelity Management and Research Company | 650756 | 1.75% | -- | -- | 2018-03-31 |
| T. Rowe Price Associates, Inc. | 759607 | 2.04% | -649597 | -46.10% | 2018-06-30 |
| Redmile Group, LLC | 1611746 | 4.33% | -442454 | -21.54% | 2018-06-30 |
| FMR Inc | 650756 | 1.75% | -- | -- | 2018-03-31 |
| Stine Seed Farm, Inc. | 7857732 | 21.25% | 780487 | 11.03% | 2017-10-06 |
| Arnhold & S. Bleichroeder Advisers, LLC | 759250 | 2.04% | -1587050 | -67.64% | 2018-06-30 |
| State Street Corp | 473743 | 1.27% | -21754 | -4.39% | 2018-06-30 |
| J.P. Morgan Investment Management Inc | 451610 | 1.21% | -28512 | -5.94% | 2018-06-30 |
| Candriam Luxembourg | 293000 | 0.79% | -- | -- | 2018-06-30 |
| Tekla Capital Management LLC | 205026 | 0.55% | -- | -- | 2018-06-30 |
| Segall Bryant & Hamill | 110624 | 0.30% | -3378 | -2.96% | 2018-03-31 |
| Merrill Lynch & Co Inc | 234580 | 0.63% | 203939 | 665.58% | 2018-03-31 |
| Deutsche Bank AG | 226307 | 0.61% | 132358 | 140.88% | 2018-03-31 |
| Alyeska Investment Group, L.P. | 247765 | 0.67% | -2233 | -0.89% | 2018-03-31 |
| Great Point Partners LLC | 233500 | 0.63% | -1753599 | -88.25% | 2018-03-31 |
| Columbia Mangmt Investment Advisers, LLC | 309282 | 0.83% | -1293 | -0.42% | 2017-12-31 |
| Perceptive Advisors LLC | 450000 | 1.21% | -- | -- | 2017-12-31 |
| venBio Select Advisor LLC | 795412 | 2.14% | 795412 | -- | 2017-12-31 |
| Millennium Management LLC | 2347359 | 6.33% | 1048752 | 80.76% | 2017-12-31 |
| Pioneer Investment Mgmt Inc | 202200 | 0.54% | 202200 | -- | 2017-12-31 |
| PDT Partners, LLC | 349981 | 1.12% | 234186 | 202.24% | 2017-09-30 |
| Marshall Wace North America LP | 387627 | 1.22% | 387627 | -- | 2017-09-30 |
| Orbimed Advisors, LLC | 831274 | 2.65% | -1014726 | -54.97% | 2017-09-30 |
| Orbimed Capital LLC | 1251400 | 4.29% | 1251400 | -- | 2016-12-31 |
| Columbus Circle Investors | 485848 | 1.55% | -105917 | -17.90% | 2017-09-30 |
| Franklin Advisers Inc | 515761 | 1.77% | -- | -- | 2016-09-30 |
| HAP Trading, LLC | 297931 | 1.02% | 70203 | 30.83% | 2016-09-30 |
| Close Finsbury Asset Management Limited | 309900 | 1.06% | 14300 | 4.84% | 2016-10-31 |
| Americo Financial Life and Annuity Ins | 100000 | 0.35% | -- | -- | 2015-12-31 |
| Bogle Investment Management L P | 219571 | 0.75% | -240575 | -52.28% | 2016-09-30 |
| Susquehanna Financial Group, LLLP | 216931 | 0.75% | -98526 | -31.23% | 2016-09-30 |
| Teachers Advisors Inc | 196307 | 0.67% | -- | -- | 2016-09-30 |
| QS Investors LLC | 183473 | 0.63% | 2639 | 1.46% | 2016-09-30 |
| Zurcher Kantonalbank | 164312 | 0.56% | 1181 | 0.72% | 2016-09-30 |
| BlackRock Inc. | 1575833 | 3.00% | 78224350 | 0.10% | 1999-11-30 |
| Charles J. Link, Jr., M.D. | 2006994 | 3.00% | 99627182 | 0.10% | 1999-11-30 |
| FMR, LLC | 2363346 | 3.00% | 117316495 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| NT R2000 Index Fund - NL | 109144 | 0.29% | 3707 | 3.52% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 667212 | 1.79% | -- | -- | 2019-06-30 |
| Vanguard Extended Market Index Fund | 382170 | 1.02% | -- | -- | 2019-06-30 |
| Vanguard VIF Small Co Gr Portfolio | 302850 | 0.81% | -- | -- | 2019-03-31 |
| DFA US Micro Cap Portfolio | 192392 | 0.52% | -- | -- | 2019-05-31 |
| State Street Russell Small Cap | 142484 | 0.38% | -- | -- | 2019-06-30 |
| Invesco FTSE RAFI US 1500 Small-Mid ETF | 114209 | 0.31% | -- | -- | 2019-07-31 |
| NT R2000 Value Index Fund - Non-Lending | 106439 | 0.29% | -- | -- | 2019-06-30 |
| QS US Small Capitalization Equity CIF | 92114 | 0.25% | -- | -- | 2019-06-30 |
| Northern Trust Russell 2000 Index DC NL | 82859 | 0.22% | 1752 | 2.16% | 2019-06-30 |
| iShares Micro-Cap ETF | 79140 | 0.21% | -- | -- | 2019-07-30 |
| NT R2000 Value Index Fund - Lending | 77959 | 0.21% | 7455 | 10.57% | 2019-06-30 |
| State Street Russell Small/Mid Cap | 63129 | 0.17% | -53300 | -45.78% | 2019-06-30 |
| Fidelity | 50052 | 0.13% | -8237 | -14.13% | 2019-03-31 |
| BlackRock Extended Equity Market | 48014 | 0.13% | -66 | -0.14% | 2019-06-30 |
| EQ/2000 Managed Volatility Portfolio | 46524 | 0.12% | -- | -- | 2019-05-31 |
| CREF Stock Account | 41798 | 0.11% | -- | -- | 2019-05-31 |
| BlackRock Russell 2000 | 48244 | 0.13% | 793 | 1.67% | 2019-03-31 |
| Schwab Small Cap Index Fund | 62762 | 0.17% | -- | -- | 2019-05-31 |
| Schwab US Small-Cap ETF | 85565 | 0.23% | -- | -- | 2018-09-21 |
| iShares Russell 2000 Value ETF | 226881 | 0.61% | -936 | -0.41% | 2019-05-31 |
| iShares Russell 2000 ETF | 562162 | 1.51% | -5300 | -0.93% | 2019-05-31 |
| iShares US Small Cap ETF (CAD-Hedged) | 567462 | 1.52% | -954 | -0.17% | 2019-05-30 |
| JPMorgan US Small Company Fund | 110100 | 0.30% | -265300 | -70.67% | 2019-03-31 |
| BSF Americas Diversified Eq Abs Ret Fd | 73488 | 0.20% | 73488 | -- | 2018-12-31 |
| Russell 2000 Index Non-Lendable Fund E | 65818 | 0.18% | 853 | 1.31% | 2019-03-31 |
| AXA 2000 Managed Volatility Portfolio | 46524 | 0.12% | -- | -- | 2019-01-31 |
| Loncar Cancer Immunotherapy ETF | 67651 | 0.18% | -167072 | -71.18% | 2018-06-20 |
| Virtus LifeSci Biotech Clinical Trls ETF | 114912 | 0.31% | 22330 | 24.12% | 2018-06-15 |
| Vanguard Russell 2000 Index Fund | 46328 | 0.12% | -528 | -1.13% | 2019-01-31 |
| DFA US Targeted Value Portfolio | 40762 | 0.11% | -- | -- | 2019-01-31 |
| Bogle Investment Management Sm Cp Gr Fd | 35740 | 0.10% | -- | -- | 2019-01-31 |
| DFA Tax-Managed US Targeted Value Port | 59821 | 0.16% | -- | -- | 2018-12-31 |
| Tekla Life Sciences Investors | 63211 | 0.17% | -- | -- | 2018-09-30 |
| Tekla Healthcare Investors | 141815 | 0.38% | -- | -- | 2018-09-30 |
| Bridgeway Ultra Small Company Market Fd | 100000 | 0.27% | -- | -- | 2018-09-30 |
| Candriam Eqs L Biotechnology | 248000 | 0.67% | -- | -- | 2018-10-31 |
| iShares Nasdaq Biotechnology ETF | 398304 | 1.07% | -780 | -0.20% | 2018-11-30 |
| AXA Rosenberg Global Small Cap Alpha Fd | 58500 | 0.16% | -34900 | -37.37% | 2018-10-31 |
| DWS Biotech | 104894 | 0.28% | 34894 | 49.85% | 2018-03-31 |
| Fidelity Advisor | 114392 | 0.31% | -- | -- | 2018-03-31 |
| Columbia VP US Equities Fund | 142700 | 0.38% | -- | -- | 2018-02-28 |
| Rhenman Healthcare Eq L/S | 181047 | 0.49% | -- | -- | 2018-03-31 |
| T. Rowe Price Small-Cap Value Fund | 628000 | 1.69% | -203900 | -24.51% | 2018-06-30 |
| Columbia Small Cap Growth Fund I | 93800 | 0.25% | -- | -- | 2018-01-31 |
| CPR Invest Global Disruptive Opps | 151100 | 0.41% | 19000 | 14.38% | 2017-12-31 |
| T. Rowe Price Small-Cap Value | 628000 | 1.69% | -203900 | -24.51% | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 715224 | 1.92% | 28591 | 4.16% | 2018-07-31 |
| JPMorgan US Small Company Instl | 414500 | 1.11% | 8100 | 1.99% | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 381345 | 1.03% | -- | -- | 2018-07-31 |
| iShares Nasdaq Biotechnology | 410568 | 0.96% | -783 | -0.19% | 2018-09-12 |
| Vanguard VIF Small Co Gr | 195928 | 0.53% | 195928 | -- | 2018-06-30 |
| iShares Russell 2000 Value | 240453 | 0.56% | -- | -- | 2018-09-12 |
| State Street Russell Small/Mid Cap Idx Fd Cl I | 73021 | 0.25% | 4100 | 5.95% | 2017-06-30 |
| Bridgeway Ultra-Small Company Market | 100000 | 0.27% | -- | -- | 2018-06-30 |
| iShares Micro-Cap | 77805 | 0.18% | -- | -- | 2018-09-12 |
| BlackRock Russell 2500 | 46826 | 0.13% | 92 | 0.20% | 2018-06-30 |
| BlackRock Extended Equity Market K | 47687 | 0.13% | 19858 | 71.36% | 2018-06-30 |
| Vanguard Health Care ETF | 64455 | 0.17% | 558 | 0.87% | 2018-07-31 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 70341 | 0.19% | -462 | -0.65% | 2018-07-31 |
| Fidelity Spartan | 58735 | 0.16% | 1827 | 3.21% | 2018-04-30 |
| Russell Small Cap Fund Class B | 91495 | 0.25% | 91495 | -- | 2018-07-31 |
| AXA 2000 Managed Volatility K | 46524 | 0.13% | -- | -- | 2018-06-30 |
| Schwab Small Cap Index | 48700 | 0.13% | -400 | -0.81% | 2018-06-30 |
| CREF Stock R1 | 129745 | 0.35% | -- | -- | 2018-04-30 |
| The Vanguard Russell 2000 Growth Index | 46228 | 0.12% | -- | -- | 2018-05-31 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 42639 | 0.11% | -- | -- | 2018-05-31 |
| iShares Russell 2000 Growth | 288435 | 0.76% | 498 | 0.17% | 2018-06-21 |
| BioShares | 92582 | 0.25% | -- | -- | 2018-06-14 |
| Columbia Small Cap Growth I Z | 93800 | 0.25% | -- | -- | 2018-01-31 |
| Columbia VP US Equities 2 | 142700 | 0.38% | -- | -- | 2018-02-28 |
| American Century Small Company Inv | 50528 | 0.14% | -- | -- | 2017-12-31 |
| QS Batterymarch US Sm Cap Eq I | 109404 | 0.35% | -- | -- | 2017-09-30 |
| Franklin Biotechnology Discovery A | 205300 | 0.70% | -- | -- | 2016-12-31 |
| TIAA-CREF Small-Cap Equity Instl | 165700 | 0.57% | 5500 | 3.43% | 2016-12-31 |
| Federated MDT Small Cap Growth A | 50629 | 0.17% | -12313 | -19.56% | 2016-09-30 |
| LVIP SSgA Small/Mid Cap 200 Svc | 64797 | 0.22% | 1404 | 2.21% | 2016-12-31 |
| BlackRock Small Cap Growth Eq Instl | 44190 | 0.15% | 22535 | 104.06% | 2016-12-31 |
| Gotham Absolute Return Fund | 569198 | 2.00% | 569198 | -- | 2015-04-30 |
| SPDR® S&P Biotech ETF | 463935 | 1.50% | 3028 | 0.70% | 2015-11-19 |
| Franklin Biotechnology Discovery | 350061 | 1.20% | -- | -- | 2015-07-31 |
| iShares Russell 2000 (AU) | 330822 | 1.10% | -420 | -0.10% | 2015-11-19 |
| Vanguard Strategic Equity Fund | 262900 | 0.90% | 71400 | 37.30% | 2015-09-30 |
| Fidelity Advisor® Biotechnology Fund | 252479 | 0.90% | -- | -- | 2015-09-30 |
| Gotham Enhanced Return Fund | 246810 | 0.90% | 246810 | -- | 2015-04-30 |
| Franklin Biotechnology Discovery Fund | 205300 | 0.70% | -25700 | -11.10% | 2015-09-30 |
| UBS (Lux) EF Biotech (USD) | 200000 | 0.70% | -- | -- | 2015-07-31 |
| Fidelity® Select Biotechnology Portfolio | 1456947 | 5.10% | -- | -- | 2015-09-30 |
| iShares US Pharmaceuticals | 187848 | 0.60% | -- | -- | 2015-11-19 |
| Paolo Pucci | Presently, Paolo Pucci is Chief Executive Officer & Director at ArQule, Inc. Mr. Pucci is also on the board of West Pharmaceutical Services, Inc. and NewLink Genetics Corp. He previously occupied the position of Senior VP-Global Specialty Medicine Business Unit at Bayer AG President-US Pharmaceutical Operations at Bayer Pharmaceuticals Corp. and Senior Vice President at Bayer Pharma AG (both are subsidiaries of Bayer AG) and Managing Director at Eli Lilly Sweden AB. Mr. Pucci received an undergraduate degree from Universit�0�1�0�2 degli Studi di Napoli Federico II and an MBA from The University of Chicago Booth School of Business. |
|---|---|
| John B. Henneman | Presently, John B. Henneman holds the position of Chief Administrative Officer at NewLink Genetics Corp. Mr. Henneman is also on the board of Alafair Biosciences, Inc., SeaSpine Holdings Corp. and R1 RCM, Inc. In his past career Mr. Henneman occupied the position of Interim Co-Chief Executive Officer & Secretary at Neuromedical Systems, Inc. and Chief Administrative Officer & Vice President at Integra LifeSciences Holdings Corp. and Chairman for Newdeal SAS (a subsidiary of Integra LifeSciences Holdings Corp.). Mr. Henneman received an undergraduate degree from Princeton University and a graduate degree from The University of Michigan Law School. |
| Paul R. Edick | Mr. Paul R. Edick is a President, Chief Executive Officer & Director at Xeris Pharmaceuticals, Inc., an Independent Director at Sucampo Pharmaceuticals, Inc., a Chairman at Iterum Therapeutics Ltd., an Independent Director at PDL BioPharma, Inc., an Independent Director at Neos Therapeutics, Inc., an Independent Director at NewLink Genetics Corp., a Managing Partner at 3G Advisors LLC and a President at Vicuron Pharmaceuticals, Inc. He is on the Board of Directors at Xeris Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., PDL BioPharma, Inc., Neos Therapeutics, Inc. and NewLink Genetics Corp. Mr. Edick was previously employed as an Independent Non-Executive Director by Circassia Ltd., an Independent Non-Executive Director by Circassia Pharmaceuticals Plc, a President, Chief Executive Officer & Director by Durata Therapeutics, Inc., a Chairman by LifeCycle Pharma A/S, a Chief Executive Officer by GANIC Pharmaceuticals, Inc., a Chairman by Life Cycle Pharma A/S, a Chief Executive Officer by MedPointe Healthcare, Inc., a President & Chief Executive Officer by MedPointe, Inc., a President-Asia Pacific & Latin America by Pharmacia Corp., a President-Asia Pacific, Canada & Latin America by G.D. Searle & Co., Inc., a Principal by Baxter Healthcare Corp., a Sales Representative by Procter & Gamble Co., and a President by MedPointe Capital Partners LLC. He also served on the board at Amerita, Inc. and Informed Medical Communications, Inc. He received his undergraduate degree from Hamilton College (New York). |
| Lisa V. DeLuca | Currently, Lisa V. DeLuca occupies the position of Vice President-Regulatory Affairs of NewLink Genetics Corp. and Vice President-Regulatory Affairs for Celator Pharmaceuticals, Inc. She previously held the position of Principal at The Upjohn Co., Principal at Wyeth Corp., Vice President-Global Regulatory Affairs at Eximias Pharmaceutical Corp., VP-Regulatory Affairs & Quality Assurance at Topaz Pharmaceuticals, Inc., Director-Regulatory Affairs at AstraZeneca Pharmaceuticals LP, Vice President-Global Regulatory Affairs at YM Biosciences USA, Inc. and Manager-Regulatory Affairs at Centocor, Inc. Lisa V. DeLuca received a doctorate from the University of Toledo (Ohio) and a graduate degree and an undergraduate degree from Eastern Michigan University. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论